Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE

Key Points

Primary adrenal insufficiency can arise from pembrolizumab treatment, posing significant health risks.
Early recognition of primary adrenal insufficiency is vital for effective intervention and management.
Analysis of a case involving a 75-year-old man showcases the clinical impact of this rare endocrine disorder.
Awareness of immune-related adverse events is crucial in improving patient outcomes during immunotherapy.

Abstract

Pembrolizumab, a PD-1 checkpoint inhibitor, is widely used in the treatment of various malignancies. While it improves overall survival, it can lead to immune-related adverse events (irAEs), including rare endocrine disorders such as primary adrenal insufficiency (PAI). We present a case of PAI induced by Pembrolizumab in a 75-year-old man, emphasizing the importance of early recognition and timely management.

Bookmark

View Full Paper

Cite This Study

Raza et al. (Sun,) studied this question.

synapsesocial.com/papers/69a765fcbadf0bb9e87db2ca https://doi.org/https://doi.org/10.53785/2769-2779.1341

Bookmark

View Full Paper